Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

WIN 2012

28 - 29 Jun 2012

France

The WINTHER study

Prof Razelle Kurzrock - MD Anderson Cancer Center, Houston, USA

The WINTHER study ( Prof Razelle Kurzrock - MD Anderson Cancer Center, Houston, USA )

Use of electronic data to raise the standard of cancer care

Brett Davis – Oracle Corporation, USA

Use of electronic data to raise the standard of cancer care ( Brett Davis – Oracle Corporation, USA )

Drugging the cancer genome: opportunities and challenges

Prof Paul Workman - Institute of Cancer Research, UK

Drugging the cancer genome: opportunities and challenges ( Prof Paul Workman - Institute of Cancer Research, UK )

A new direction for development of targeted cancer therapies

Dr Edison Liu – Jackson Laboratory, USA

A new direction for development of targeted cancer therapies ( Dr Edison Liu – Jackson Laboratory, USA )

Online collaborations to aid treatment development

Dr Patrick Johnson - Dassault Systems, France

Online collaborations to aid treatment development ( Dr Patrick Johnson - Dassault Systems, France )

Addressing Asia’s high cancer incidence

Dr Bin Teh - SingHealth Group, Singapore

Addressing Asia’s high cancer incidence ( Dr Bin Teh - SingHealth Group, Singapore )

Vandetanib increases progression free survival in medullary thyroid carcinoma

Dr Nick Botwood - AstraZeneca, UK

Vandetanib increases progression free survival in medullary thyroid carcinoma ( Dr Nick Botwood - AstraZeneca, UK )

WINTHER: The WIN therapeutics clinical trial

Prof Josep Tabernero - Vall d'Hebron Institute of Oncology (VHIO), Barcelona...

WINTHER: The WIN therapeutics clinical trial ( Prof Josep Tabernero - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Use of genetic variance to identify potential therapeutic targets

Dr John Quackenbush - Dana-Farber Cancer Institute, Boston, USA

Use of genetic variance to identify potential therapeutic targets ( Dr John Quackenbush - Dana-Farber Cancer Institute, Boston, USA )

Introduction of PET tracers to the WINTHER trial

Robert Dann - Global Strategy Leader, Oncology/Pathology, GE Healthcare

Introduction of PET tracers to the WINTHER trial ( Robert Dann - Global Strategy Leader, Oncology/Pathology, GE Healthcare )

Application of next generation sequencing

Dr Gary Palmer – Foundation Medicine, Cambridge, USA

Application of next generation sequencing ( Dr Gary Palmer – Foundation Medicine, Cambridge, USA )

Next generation sequencing and WIN therapeutics

Dr Michael Pellini – Foundation Medicine, Cambridge, USA

Next generation sequencing and WIN therapeutics ( Dr Michael Pellini – Foundation Medicine, Cambridge, USA )

Identifying targets with systems medicine

Dr Leroy Hood – Institute for Systems Biology, USA

Identifying targets with systems medicine ( Dr Leroy Hood – Institute for Systems Biology, USA )

Importance of early detection and the ‘Beyond the Shock’ programme

Dr Douglas Feil – National Breast Cancer Foundation, USA

Importance of early detection and the ‘Beyond the Shock’ programme ( Dr Douglas Feil – National Breast Cancer Foundation, USA )

Shortening the timeline for clinical drug developments

Dr James Doroshow – National Cancer Institute, Bethesda, USA

Shortening the timeline for clinical drug developments ( Dr James Doroshow – National Cancer Institute, Bethesda, USA )

Building international collaborations and the WINTHER trial

Dr Oliver Bogler – MD Anderson Cancer Center, Houston, USA

Building international collaborations and the WINTHER trial ( Dr Oliver Bogler – MD Anderson Cancer Center, Houston, USA )

More from ecancer